Last updated: February 13, 2026
Product Overview
NDC 00093-0311 corresponds to Xyrem (sodium oxybate), marketed by Jazz Pharmaceuticals. The drug is primarily used to treat narcolepsy and has orphan drug designation, which influences its market dynamics and pricing strategies. As of 2023, Xyrem is a controlled substance with scheduled classification due to its abuse potential, impacting its distribution and pricing.
Market Size and Demand
Xyrem's primary indications include narcolepsy with cataplexy. The narcolepsy prevalence globally is estimated between 25 to 50 cases per 100,000, with higher diagnosis rates in the U.S. and Europe.
- U.S. Market: Approximate population of 330 million. Estimated narcolepsy patients range from 82,500 to 165,000.
- Prescription Trends: Data from IQVIA indicates Xyrem accounts for a majority of narcolepsy-related prescriptions, with approximately 50,000 to 60,000 prescriptions annually in the U.S. in recent years.
Global markets are emerging, but U.S. dominance persists due to higher diagnosis rates and approved indications.
Market Competition
Xyrem’s main competitor is Sodium oxybate formulations from other manufacturers, including generics. However, no generic versions of Xyrem have been FDA-approved due to patent protections and orphan drug exclusivity.
- Patent Landscape: Key patents extended till 2025, with some exclusivity periods through orphan designation.
- Generics: Limited competition exists mainly through off-label or unregulated compounds but no generic entries legally market Xyrem under the same formulation.
Pricing and Revenue
The wholesale acquisition cost (WAC) for Xyrem is approximately $42,000 per year per patient (2023 data), but actual prices paid vary due to insurance, discounts, and patient assistance programs.
| Parameter |
Data/Estimate |
| Average annual cost per patient |
$42,000 |
| U.S. patient population |
~80,000 to 110,000 (diagnosed and treated) |
| Total U.S. market revenue |
$3.4 billion to $4.6 billion (annual) |
Outside the U.S., prices are generally lower, with European markets charging approximately 70-80% of U.S. prices.
Pricing Projections
Market exclusivity and demand stability suggest steady pricing within the current range. Post-expiry of key patents (expected in 2025), price competition might lower costs by 10-20% over the subsequent 2-3 years if generics enter successfully.
Future Trends
- Patent Expiry and Generics: Potential to disrupt pricing post-2025.
- New Formulations: Development of longer-acting or nasal spray versions (e.g., Xywav) might alter market dynamics and pricing.
- Regulatory Changes: Increasing restrictions on controlled substances could impact prescription volumes and revenue.
Summary
NDC 00093-0311 (Xyrem) commands a high price point driven by limited competition, orphan drug status, and demand in narcolepsy treatment. The market is expected to remain stable until patent expiry, after which competition may reduce prices by 10-20%.
Key Takeaways
- Xyrem's U.S. annual revenue is approximately $3.4 billion to $4.6 billion based on current pricing and demand.
- No generics are available before 2025 due to patent protections.
- Pricing is expected to decline marginally once patents expire, barring new formulation launches.
- Global markets have lower prices, but the U.S. remains dominant.
- Market size depends on narcolepsy diagnosis rates and adherence to treatment.
FAQs
1. When will generic versions of Xyrem become available?
Patent protections are expected to expire in 2025, after which generic manufacturers can apply for approval.
2. How does orphan drug status impact Xyrem's market?
Orphan designation grants exclusivity for 7 years post-approval in the U.S., delaying generic competition and sustaining high prices.
3. Are there alternative treatments to Xyrem?
Yes, drugs like Sodium oxybate (low sodium version) and other narcolepsy therapies exist but are typically less effective or have different side effect profiles.
4. How might regulatory changes affect future pricing?
Increased regulation and monitoring of controlled substances could lead to reduced prescriptions, impacting revenue.
5. What is the potential impact of new formulations?
New delivery forms like nasal sprays or longer-acting variants could capture market share and influence pricing trajectories.
Sources
[1] IQVIA Prescription Data (2022-2023)
[2] FDA Patent and Exclusivity Announcements
[3] Jazz Pharmaceuticals Financial Reports (2022-2023)
[4] Global narcolepsy epidemiology studies
